Talecris launches IPO

Talecris Biotherapeutics has launched its ice-breaking IPO, saying it will sell 44.7 million shares at $18 to $20 per share. Analysts say the life sciences offering is solid proof that the once frozen market has begun to thaw and the Research Triangle Park-based company is leading the way. Release | Report